Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Seasonal Influenza Vaccines Drug Forecast and Market Analysis to 2028 - ResearchAndMarkets.com

December 3, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--

The “Seasonal Influenza Vaccines: Global Drug Forecast and Market Analysis to 2028” report has been added to ResearchAndMarkets.com’s offering.

During the 10-year forecast period, there are nine pipeline products that are on track to launch, driving a forecast growth in the 8MM from $4.6b in 2018 to $6.5b in 2028, which represents a CAGR of 3.7%.

Seasonal influenza is a viral infection that occurs annually in the winter months from December to March/April in the Northern Hemisphere and from May to August/September in the Southern Hemisphere. Two types of influenza virus, type A and B, are responsible for the majority of seasonal influenza infections in humans, and due to frequent virus mutations annual vaccination is recommended.

The WHO estimates three to five million cases of severe seasonal influenza infections and 290,000 to 650,000 influenza-related respiratory deaths, most of them in the elderly population. Therefore, many countries recommend annual immunization against seasonal influenza, especially for high-risk groups such as young children, pregnant women, elderly people, and people with chronic diseases.

Immunization provides the best protection against the influenza virus and vaccines have been available for decades with a recent switch from trivalent to quadrivalent vaccines that protect against each two influenza type A and two B strains. Traditionally, seasonal influenza vaccines have been produced in eggs, but a slow manufacturing process and viral egg-adaptations have led to a push for cell-based and recombinant vaccine production methods in recent years.

Key Questions Answered

Key Highlights


Reasons to Buy

Key Topics Covered:

1. List of Tables & Figures

2 Seasonal Influenza Vaccines: Executive Summary

2.1 Modest Growth Expected for the Seasonal Influenza Vaccine Market over the Forecast Period from 2018-2028

2.2 Transition from Egg-Based to Cell Culture-Based and Recombinant Seasonal Influenza Vaccines Is Underway

2.3 Seasonal Influenza Vaccine Efficacy and Vaccine Hesitancy

2.4 Non-egg-based Vaccines Will Take 38% of the 8MM Influenza Vaccine Market by 2028

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.3.4 Brazil

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Seasonal Influenza (2018-2028)

5.5.1 Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza

5.5.2 Age-Specific Diagnosed Incident Cases of Disease of Lab-Confirmed Seasonal Influenza

5.5.3 Sex-Specific Diagnosed Incident Cases of Lab-Confirmed Seasonal Influenza

5.5.4 Lab-Confirmed Seasonal Influenza Mortality

5.5.5 Age-Specific Vaccination of Seasonal Influenza

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Overview

6.2 US

6.3 5EU

6.3.1 France

6.3.2 Germany

6.3.3 Italy

6.3.4 Spain

6.3.5 UK

6.4 Japan

6.5 Brazil

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Enhanced Vaccine Efficacy in High-Risk Groups

8.3 Public Opinion of Seasonal Influenza Vaccines: Awareness, Hesitancy, and Skepticism

8.4 Immunization Policies Targeting Children and Adolescents

8.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

8.6 Vaccines with Broader Influenza Strain Coverage

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Other Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Portfolio Assessment

10.3.1 Sanofi

10.3.2 Seqirus (CSL Limited)

10.3.3 GlaxoSmithKline

10.3.4 Mylan

10.3.5 AstraZeneca

10.3.6 Mitsubishi Tanabe Pharma

10.3.7 Other Companies

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers - Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Brazil

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/6op2r2

View source version on businesswire.com:https://www.businesswire.com/news/home/20191203005658/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/03/2019 09:21 AM/DISC: 12/03/2019 09:21 AM